U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H24FN3O4
Molecular Weight 389.4207
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BALOFLOXACIN

SMILES

CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O

InChI

InChIKey=MGQLHRYJBWGORO-UHFFFAOYSA-N
InChI=1S/C20H24FN3O4/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27)

HIDE SMILES / InChI

Molecular Formula C20H24FN3O4
Molecular Weight 389.4207
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Balofloxacin (Q-35), is an orally active fluoroquinolone antibiotic. It has been developed for the treatment of urinary tract infection. The bactericidal action of Balofloxacin results from interference with the enqyme DNA gyrase which is needed for the synthesis of bacterial DNA. Balofloxacin is efficacious against Gram-negative bacteria. It also has enhanced activity against Gram positive bacteria, including MRSA and Streptococcus pneumoniae. Side effects of Balofloxacin are: sensitivity to light, abdominal pain, nausea, heartburn, urticarial, irritation when applied locally. Balofloxacin may interact with the following medicines and salts: antacids, non-steroidal anti-inflammatory drug, quinolones, theophylline.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Q-Roxin
Curative
Unknown
Curative
Barofloxacin
Curative
Balofloxacin

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
100 to 400 mg once or twice daily.
Route of Administration: Oral
In Vitro Use Guide
MIC90 of Balofloxacin against clinical isolates of Staphylococcus aureus, methicillin-resistant staphylococcus aureus (MRSA), Staphylococcus epidermidis, Streptococcus pneumoniae, and Streptococcus pyogenes is 6,25 ug/ml.
Substance Class Chemical
Record UNII
Q022B63JPM
Record Status Validated (UNII)
Record Version